CClinicalTrials.gg
TerminatedNCT02513823Updated Oct 4, 2019Results posted

Effectiveness of Vitamin D Supplementation

An interventional study of 2,000 International Units (IU)of vitamin D3 in Elevated Blood Pressure and Endothelial Dysfunction, sponsored by Texas Woman's University. Terminated at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-10-04.

Sponsored by Texas Woman's University · Not applicable, Interventional, and Prevention

Why this study was terminated
Reached power analysis goal and funds depleted
Phase
Not applicable
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

This pilot study will examine the effectiveness of vitamin D supplementation on reducing blood pressure and improving endothelial function. Premenopausal African American women will be recruited. Participants will be instructed to record food intake for three days to estimate usual dietary intake at baseline and at the 10th week. At the baseline clinic visit a 10 week supply of vitamin D3 supplements (2,000 IU/day; Nature Made ®) will be given to participants and log sheets provided to record supplement intake. To answer the primary research questions, within subjects repeated measures analysis of variance (ANOVA) tests will be conducted to test if any differences in blood pressure, serum 25(OH)D concentrations, and RHI are statistically different after 10 weeks of supplementation with 2,000 IU/d of vitamin D. Exploratory multivariate linear regression models will be constructed to determine relationships between vitamin D status and vascular function parameters (blood pressure, RHI) before and after adjustment for age and BMI.

Read the detailed description

This pilot study will examine the effectiveness of vitamin D supplementation on reducing blood pressure and improving endothelial function. If results of the pilot study are favorable, findings will be used to design a possibly larger study to confirm results. Premenopausal African American women (n = 40) will be recruited. All participant study visits will be held at the Houston Methodist Internal Medicine Clinic or at the TWU Nutrition Laboratory. African American women will be recruited who are not taking hypertensive medications, have average blood pressure measurements \< 140/90 mmHg, are not pregnant or planning on becoming pregnant in the next three months, or who are not lactating.

Enrollment Visit The day prior to the enrollment visit potential subjects will fast overnight and refrain from consuming any caffeinated products, vitamins, or medications that may affect vascular tone and refrain from smoking. the investigators will explain the 10 week study design and obtain participant consent. Testing will be performed in the morning with start times between 8 and 10:00 a.m. In a quiet and temperature-controlled room (72° to 75° F), initial systolic and diastolic blood pressure measurements following 5 minutes of seated rest following the American Heart Association Blood Pressure Guidelines. The arm will be supported at heart level and neither participant nor observer will talk during the measurements. Three successive measurements will be collected with an automated oscillometric sphygmomanometer and the average of the last two measurements will be calculated. Any individual with an average blood pressure > 140/90 mmHg will be referred to their personal physician for follow up.

Consented participants with blood pressure readings \<140/90 mmHg will be instructed to consume their usual diet for the next week and to complete a three-day diet record of two week days and one weekend. Instructions on how to record the dietary diary will be given. Food records will be used to estimate usual dietary intake for the baseline and 10 week time points. An appointment will be scheduled for the participant to return with completed food records to begin the intervention study. At the baseline clinic visit a 10 week supply of vitamin D3 supplements (2,000 IU/day; all the same lot; Nature Made ®) will be given to participants and log sheets provided to record supplement intake. In addition, participants will be instructed to avoid traveling to sunny locations for 10 weeks.

Baseline and 10 week clinic visits

Nutrient intake:

Three-day diet records will be collected during the baseline and 10 week clinic visits. Food records will be analyzed at TWU utilizing the University of Minnesota 2015 Nutrient Data System for Research. Total energy intake; percent calories from fat, protein and carbohydrates; and intake of vitamins A, C, D, E and beta carotene will be estimated from food records.

Blood pressure measurements:

Participants will fast overnight and refrain from consuming any caffeinated products, vitamins, medications that may affect vascular tone, or smoking. Testing will be performed in the morning with start times between 8 and 10:00 a.m. In a quiet and temperature-controlled room (72° to 75° F), initial systolic and diastolic blood pressure measurements will be taken following 5 minutes of seated rest following the American Heart Association Blood Pressure Guidelines. The arm will be supported at heart level and neither participant nor observer will talk during the measurements. Three successive measurements will be collected with an automated oscillometric sphygmomanometer and the average of the last two measurements will be calculated.

Body fat and adiposity measures:

Anthropometric and body fat distribution assessments will be performed. Height and weight will be measured. Percent body fat will be determined by bioelectric impedance (Tanita BF-350). Body mass index (BMI) will be calculated as weight in kilograms (kg) divided by height squared (m2).

Endothelial pulse amplitude measurements:

Pulse amplitude tonometry (PAT) will be measured with the EndoPAT 2000 (Itamar Medical Ltd) which records digital pulse wave amplitude (PWA) using fingertip plethysmography (16). The Endo-PAT finger probe consists of a thimble-shaped sensor cap that imparts a uniform pressure field and exhibits a clamp-like effect on the entire surface of the distal phalanx and measured pulsatile volume changes. PWA is measured continuously during three phases: a quiet baseline period, 5-minute forearm occlusion, and reactive hyperemia following cuff release. Occlusion of the brachial artery is performed on the non-dominant upper arm. The continuous monitoring of blood volume reaching the finger tips allows the hyperemic response to be quantified as a ratio, comparing PWA from pre to post occlusion. A reactive hyperemia index (RHI) measures nitric-oxide dependent changes in vascular tone. The recordings from the non-occluded arm serve as a control for changes in overall physiological state. The Endo-PAT RHI index is defined as the ratio of the average PWS during the 1 minute period beginning after exactly 90 second to reactive hyperemia compared with the average pulse amplitude during the 210 second pre-occlusion baseline period. Endothelial dysfunction is classified as a RHI \< 1.67 with average normal endothelial RHI values ranging between 1.7 and 2.0.

Vitamin D measurements:

Blood will be drawn by Houston Methodist Hospital laboratory for measurement of serum 25(OH)D concentrations by chemiluminescence immunoassay( Abbott Architect). Vitamin D deficiency will be defined as serum 25(OH)D levels less than 20 ng/mL (50 nmol/L) and vitamin D insufficiency as 21 to 29 ng/mL (50 to 80 nmol/L).

Statistical analyses:

Descriptive statistics, including means and standard deviations for continuous variables and frequencies and percentages for categorical variables, will be calculated for study variables. Age, BMI, blood pressure, serum 25(OH)D concentration, and RHI will be treated as continuous variables. Prior to conducting primary analyses, exploratory and preliminary analyses will be conducted to test the statistical assumptions of planned analyses. Specifically, these assumptions include normality, homogeneity of variance, equivalent group size, and data that is missing by random. In the event that any of these assumptions have been violated, the data will either be transformed to meet the parametric assumptions of planned analyses or non-parametric equivalencies will be conducted as an alternative. In addition, correlation analyses, including Pearson's product moment correlations for normally distributed variables and Spearman's rho for non-normally distributed variables, will be conducted to examine the variables for potentially collinear relationships, which may impact primary analyses.

To answer the primary research questions, within subjects repeated measures analysis of variance (ANOVA) tests will be conducted to test if differences in blood pressure, serum 25(OH)D concentrations, and RHI are statistically different after 10 weeks of supplementation with 2,000 IU/d of vitamin D. Furthermore, exploratory multivariate linear regression models will be constructed to determine relationships between vitamin D status and vascular function parameters (blood pressure, RHI) before and after adjustment for age and BMI. All statistical analyses will be performed using Statistical analyses SPSS (version 19; SPSS IBM) and p \< 0.05 will be used to determine statistical significance.

A priori power analyses was conducted using G*Power (v. 3.0.10) in order to determine an adequate sample size to detect statistical significance if significance in fact exists. In order to obtain a desired level of power at .80, estimating a moderate effect size (.25) and an alpha level of .05, a total of 22 participants will be needed to to ensure a statistically significant increase in serum 25(OH)D concentrations. Accounting for attrition of approximately 15%, a total of 25 participants will be recruited. Repeated measures-ANOVAs will be utilized to detect significant changes across the following outcome variables: serum 25(OH)D, blood pressure, and RHI. As such, a total of 25 participants should be sufficient to detect significance if significance in fact exists across all planned analyses.

02

Conditions studied

  • Elevated Blood Pressure
  • Endothelial Dysfunction

Browse trials for

Keywords

  • blood pressure
  • vitamin D
03

In context

Hypertension

6,689 studies on the registry are indexed under Hypertension; 965 are open to participants now.

This study's enrollment of 27 is below the median of 90 across 4,995 interventional studies indexed under Hypertension.

Browse Hypertension studies →

Lead sponsor

Texas Woman's University is the lead sponsor of 82 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Healthy pre-menomausal African American women

Exclusion criteria

Exclusion Criteria:

  • History of elevated blood pressure >140/90 mm Hg
  • Pregnant or planning to become pregnant in the next three months
  • Lactating
  • Known Crohn's
  • Inflammatory bowel disease
  • Previous bowel resections
  • Bariatric surgeries, or psoriasis
  • Artificial or long fingernails they do not want to cut for testing
  • Regularly taking medications that might affect endothelial function such as anti-inflammatory medications, statins, anti-hypertensive medication, daily aspirin, non-SSRI psychotropic medication, and dietary supplements including vitamin D supplements
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Intervention

    2,000 IU of vitamin D given to African American women for 10 weeks

    Dietary Supplement: 2,000 International Units (IU)of vitamin D3

Interventions

  • Dietary supplement2,000 International Units (IU)of vitamin D3

    2,000 IU vitamin D taken daily for 10 weeks

06

What researchers measure

Primary outcomes

  1. Effectiveness of Vitamin D Supplementation on Reducing Blood Pressure

    Changes in systolic and diastolic blood pressure will be measured at baseline and following vitamin D supplementation for 10 weeks in African American healthy pre-menopausal women

    Time frame: Baseline and 10 weeks

Secondary outcomes

  1. Effectiveness of Vitamin d Supplementation on Improving Endothelial Function

    Changes of endothelial function at baseline and following 10 weeks of vitamin D supplementation as measured by pulse amplitude tonometry (PAT) fingertip plethysmography. Endothelial dysfunction was classified as a Reactive Hyperemic Index (RHI) of \< 1.67 . RHI scale typical ranges from 1.0 to 3.0.

    Time frame: Baseline and 10 weeks

07

Results

Posted Oct 4, 2019

Participant flow

Participant flow — Overall Study
MilestoneIntervention
Started27
Completed22
Not completed5
Withdrew: Lost to follow-up4
Withdrew: Physician decision1

Outcome measures

PrimaryEffectiveness of Vitamin D Supplementation on Reducing Blood Pressure

Changes in systolic and diastolic blood pressure will be measured at baseline and following vitamin D supplementation for 10 weeks in African American healthy pre-menopausal women

Time frame:
Baseline and 10 weeks
Reported as:
Mean · mmHg
Effectiveness of Vitamin D Supplementation on Reducing Blood Pressure
mmHgIntervention
SPB at Baseline124 ± 12
SBP at 10 Weeks125 ± 10
DBP at baseline79 ± 11
DBP at 10 weeks81 ± 10
SecondaryEffectiveness of Vitamin d Supplementation on Improving Endothelial Function

Changes of endothelial function at baseline and following 10 weeks of vitamin D supplementation as measured by pulse amplitude tonometry (PAT) fingertip plethysmography. Endothelial dysfunction was classified as a Reactive Hyperemic Index (RHI) of \< 1.67 . RHI scale typical ranges from 1.0 to 3.0.

Time frame:
Baseline and 10 weeks
Reported as:
Mean · units on a scale
Effectiveness of Vitamin d Supplementation on Improving Endothelial Function
units on a scaleIntervention
Reactive Hyperemia Index Baseline2.1 ± 0.6
Reactive Hyperemia Index 10 Weeks2.0 ± 0.5

Adverse events

Collected over 10 weeks over the vitamin D supplementation period. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Intervention—0/23 (0%)0/23 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Intervention
<=18 years0
Between 18 and 65 years22
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)Intervention
Female22
Male0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Intervention
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American22
White0
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Intervention
United States22
08

Study locations

1 site
  • Methodist Hospital
    Houston, Texas 77030, United States
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 4, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02513823
Lead sponsor
Texas Woman's University
Collaborators
The Methodist Hospital Research Institute
Responsible party
Carolyn Moore (Associate Professor, Texas Woman's University) — Principal investigator
First posted
Aug 3, 2015
Start date
Dec 1, 2015
Primary completion
Aug 1, 2016
Completion
Oct 14, 2016
Results posted
Oct 4, 2019
Last update
Oct 4, 2019

Study contacts

Carolyn Moore, PHD, RD, LD
principal investigator · Methodist Hosptial

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion